Erlotinib治疗肝癌的临床研究进展

高帆; 祁兴顺

doi:10.3969/j.issn.1001-5256.2015.06.039

Erlotinib治疗肝癌的临床研究进展

DOI: 10.3969/j.issn.1001-5256.2015.06.039

高帆,
祁兴顺

1. 解放军第二O二医院医务处
2. 沈阳军区总医院消化内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2611
- HTML全文浏览量: 7
- PDF下载量: 502
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Clinical research progress in Erlotinib treatment for hepatocellular carcinoma

摘要

摘要: Erlotinib可以选择性抑制表皮生长因子受体,以发挥抗肿瘤活性。总结了Erlotinib治疗肝癌的Ⅱ-Ⅲ临床试验结果。两项Ⅱ期临床试验提示Erlotinib单药治疗肝癌的疗效适中,两项来自美国的Ⅱ期临床试验发现Erlotinib联合Bevacizumab治疗肝癌可以达到较好的疗效,但其潜在增加静脉曲张出血的风险,而两项来自亚洲的Ⅱ期临床试验显示Erlotinib联合Bevacizumab治疗肝癌的疗效欠佳。最近,一项随机对照Ⅲ期试验并未能证实Erlotinib可以显著改善索拉非尼治疗肝癌的总体生存时间。未来的研究应根据临床及分子预后标志物去选择适合接受Erlotinib的肝癌患者,以更有效地鉴定Erlotinib适用人群。
- 癌,肝细胞 /
- 临床试验 /
- 厄洛替尼 /
- 综述
Abstract: Erlotinib achieves antitumor activity by selective inhibition of the epidermal growth factor receptor. This paper summarizes the results of phase Ⅱ- Ⅲ clinical trials of erlotinib in the treatment of hepatocellular carcinoma( HCC). Two phase Ⅱ clinical trials demonstrated the modest antitumor activity of erlotinib alone in patients with HCC. Additionally,two phase Ⅱ clinical trials conducted in the USA showed the excellent efficacy of erlotinib combined with bevacizumab for HCC,but with an increased risk of variceal bleeding. By contrast,two phase Ⅱ clinical trials conducted in Asia showed the poor efficacy of erlotinib combined with bevacizumab for HCC. Recently,a randomized controlled phase Ⅲ trial failed to confirm any substantial improvement in overall survival time in HCC patients treated with sorafenib combined with erlotinib compared with sorafenib alone. Future studies should identify the candidates for erlotinib among patients with HCC based on the clinical and molecular prognostic biomarkers.
- carcinoma,hepatocellular /
- clinical trial /
- erlotinib /
- review

HTML全文

参考文献(16)

[1]HERBST RS.Erlotinib[J].Clin Adv Hematol Oncol,2005,3(2):125-141.

[2]CAPPUZZO F,CIULEANU T,STELMAKH L,et al.Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre,randomised,placebo-controlled phase 3 study[J].Lancet Oncol,2010,11(6):521-529.

[3]MOORE MJ,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966.

[4]PHILIP PA,MAHONEY MR,ALLMER C,et al.Phase II study of Erlotinib(OSI-774)in patients with advanced hepatocellular cancer[J].J Clin Oncol,2005,23(27):6657-6663.

[5]THOMAS MB,CHADHA R,GLOVER K,et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma[J].Cancer,2007,110(5):1059-1067.

[6]THOMAS MB,MORRIS JS,CHADHA R,et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma[J].J Clin Oncol,2009,27(6):843-850.

[7]PHILIP PA,MAHONEY MR,HOLEN KD,et al.Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer[J].Cancer,2012,118(9):2424-2430.

[8]HSU CH,KANG YK,YANG TS,et al.Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma:a multicenter phase II study[J].Oncology,2013,85(1):44-52.

[9]YAU T,WONG H,CHAN P,et al.Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease[J].Invest New Drugs,2012,30(6):2384-2390.

[10]SANDLER AB,JOHNSON DH,HERBST RS.Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer[J].Clin Cancer Res,2004,10(12 Pt 2):4258s-4262s.

[11]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[12]KASEB AO,GARRETT-MAYER E,MORRIS JS,et al.Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome:final results of a phase II trial[J].Oncology,2012,82(2):67-74.

[13]ZHU AX,ROSMORDUC O,EVANS TR,et al.SEARCH:A phase III,randomized,double-blind,placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(6):559-566.

[14]QI XS,YANG M,BAI W,et al.Brivanib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):222-224.(in Chinese)祁兴顺,杨曼,白苇,等.Brivanib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):222-224.

[15]QI XS,JIA J,LIU L,et al.Regorafenib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):225-227.(in Chinese)祁兴顺,贾佳,刘雷,等.Regorafenib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):225-227.

[16]QI XS,JIA J,HAN GH,et al.Sunitinib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].Clin J Gastroenterol,2014,19(3):169-172.(in Chinese)祁兴顺,贾佳,韩国宏,等.舒尼替尼治疗肝细胞癌的临床研究现状[J].胃肠病学,2014,19(3):169-172.

施引文献

资源附件(0)

访问统计